Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PPM1B | O75688 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8414748 | 0.93 | KMO (0.64) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL26154174 | 0.93 | KMO (0.59) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL1787841 | 0.92 | KMO (0.67) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL30488777 | 0.89 | HTR2C (0.57) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL233530 | 0.89 | HTR2C (0.57) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL1365739 | 0.89 | KMO (0.48) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| SCHEMBL31706124 | 0.89 | HTR2C (0.57) | KMOTSHRLOXL2CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL975329 | 0.88 | HTR2C (0.58) | KMOLOXL2ALDH1A1KDM4EKMT2A | |
| SCHEMBL26471704 | 0.88 | KMT2A (0.50) | KMOALDH1A1KDM4EKMT2APOLB | |
| SCHEMBL29163107 | 0.87 | LOXL2 (0.46) | KMOTSHRLOXL2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423741-B | aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-109206417-B | Opioid receptor agonists and uses thereof | 四川海思科制药有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115124520-A | Opioid receptor agonists and uses thereof | 四川海思科制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114423741-A | aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| CN-112341399-A | 1,2, 4-triazole derivative compounds and application thereof in treating inflammatory bowel diseases | 王健 | 2021-02-09 | — | — | CN | disclosed |
| CN-109206417-A | Opioid receptor agonists and uses thereof | 四川海思科制药有限公司 | 2019-01-15 | — | — | CN | disclosed |
| WO-2017046739-A1 | IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046739-A1 | IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| EP-1966174-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1831198-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1828147-A1 | QUINOXALINES AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007071955-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1789399-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | KMO 4117/4885TSHR 4463/4885LOXL2 664/4885 |
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | KMO 2682/4885TSHR 4042/4885LOXL2 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.